Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Summary

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

Timeline

Start

2025-06

Primary completion

2027-12

Completion

2040-01

Drugs

Indications